Long-term Safety Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

This study is enrolling participants by invitation only. This is an open-label,
international, long-term safety extension study for eligible subjects who have participated
in one of the Aimmune AR101 clinical studies.

Key Inclusion Criteria:

- Prior participation in an Aimmune AR101 clinical study or any future clinical study
that identifies ARC008 as a follow-on study option in the protocol

- Written informed consent and/or assent from subjects/guardians as appropriate

- Use of effective birth control by sexually active female subjects of childbearing
potential

Key Exclusion Criteria:

- Did not complete a minimum of 3 months of AR101 maintenance therapy if the subject was
assigned to AR101 in the parent study

- Early discontinuation from the parent study

- Currently receiving or received within 5 years prior to Screening any type of peanut
or other food allergen immunotherapy, except AR101 or unless specified in the parent
study